AUTHOR=Al-Harazi Olfat , Kaya Ibrahim H. , Al-Eid Maha , Alfantoukh Lina , Al Zahrani Ali Saeed , Al Sebayel Mohammed , Kaya Namik , Colak Dilek 

TITLE=Identification of Gene Signature as Diagnostic and Prognostic Blood Biomarker for Early Hepatocellular Carcinoma Using Integrated Cross-Species Transcriptomic and Network Analyses

JOURNAL=Frontiers in Genetics

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.710049

DOI=10.3389/fgene.2021.710049

ISSN=1664-8021

ABSTRACT=<p><bold>Background:</bold> Hepatocellular carcinoma (HCC) is considered the most common type of liver cancer and the fourth leading cause of cancer-related deaths in the world. Since the disease is usually diagnosed at advanced stages, it has poor prognosis. Therefore, reliable biomarkers are urgently needed for early diagnosis and prognostic assessment.</p><p><bold>Methods:</bold> We used genome-wide gene expression profiling datasets from human and rat early HCC (eHCC) samples to perform integrated genomic and network-based analyses, and discovered gene markers that are expressed in blood and conserved in both species. We then used independent gene expression profiling datasets for peripheral blood mononuclear cells (PBMCs) for eHCC patients and from The Cancer Genome Atlas (TCGA) database to estimate the diagnostic and prognostic performance of the identified gene signature. Furthermore, we performed functional enrichment, interaction networks and pathway analyses.</p><p><bold>Results:</bold> We identified 41 significant genes that are expressed in blood and conserved across species in eHCC. We used comprehensive clinical data from over 600 patients with HCC to verify the diagnostic and prognostic value of 41-gene-signature. We developed a prognostic model and a risk score using the 41-geneset that showed that a high prognostic index is linked to a worse disease outcome. Furthermore, our 41-gene signature predicted disease outcome independently of other clinical factors in multivariate regression analysis. Our data reveals a number of cancer-related pathways and hub genes, including <italic>EIF4E, H2AFX, CREB1, GSK3B, TGFBR1,</italic> and <italic>CCNA2</italic>, that may be essential for eHCC progression and confirm our gene signature’s ability to detect the disease in its early stages in patients’ biological fluids instead of invasive procedures and its prognostic potential.</p><p><bold>Conclusion:</bold> Our findings indicate that integrated cross-species genomic and network analysis may provide reliable markers that are associated with eHCC that may lead to better diagnosis, prognosis, and treatment options.</p>